Australia Sues 3M for Over A$2 Billion Over PFAS Firefighting Foam Contamination 
Oil Prices Set for Sharp Weekly Losses as U.S.-Iran Ceasefire Hopes Ease Supply Concerns 
SK Hynix Joins $1 Trillion Club as AI Chip Demand Fuels Stock Surge 
Iran-U.S. Nuclear Talks Remain Unresolved as Strait of Hormuz Risks Keep Markets on Edge 
Meta Subscription Push Could Add Billions in Recurring Revenue, Says Rosenblatt 
Autodesk Beats Q1 Estimates, Acquires MaintainX for $3.6 Billion 
Snowflake Stock Soars 30% After Q1 Earnings Beat and Major AWS AI Partnership 
Dell Raises 2027 Revenue Forecast as AI Server Demand Drives Record Quarterly Results 
US Dollar Slips as Markets Weigh Potential US-Iran Peace Deal and Oil Price Outlook 
HP Q2 2026 Earnings Beat Expectations Despite Memory Chip Pressure 
Canada and Germany Advance Major LNG Supply Partnership 
Mega IPOs Like SpaceX and OpenAI Could Reshape S&P 500 and Nasdaq 100 Portfolios in 2026 
Asian Stocks Rally as AI Boom and Iran Ceasefire Progress Lift Market Sentiment 
MongoDB Q1 FY2027 Earnings Beat Expectations, Raises Full-Year Outlook 
US Quantum Stocks Surge After $2 Billion Government Investment 
European EV Sales Surge in April 2026 as Tesla and Chinese Automakers Gain Ground 
Salesforce Q1 FY2027 Earnings Beat Expectations Despite Soft Q2 Revenue Outlook 
SK pharmteco, a global Contract Development and Manufacturing Organization (CDMO) and a subsidiary of SK Inc., just launched its second production plant in France. With this new facility, it has now increased its production of viral vectors to double.
The Korea Economic Daily, Yposkesi, an SK pharmteco's subsidiary and one of Europe's largest CDMOs for viral vector manufacturing in Cell and Gene Therapies, finished up the construction of the new 5,000 square meter facility for industrial bioproduction for cell and gene therapy.
It was added that Yposkesi is planning to launch the commercial operations of the vector factory in 2024. A total of $65.3 million was put in for the construction of this facility. The companies may now produce up to 75 batches of cell and gene therapy products per year.
These productions are said to be one of the most advanced personalized types of medicine for the treatment of rare disorders and serious illnesses. The demand for such treatments is growing as they were proven to be effective and with fewer side effects too. These give good results since they are made with patients' own genes and cells.
"It is with great pleasure and pride that today we open the new Yposkesi viral vector manufacturing facility. This twin site enables us to stay up to pace with demand by producing larger quantities of C> products approved for commercialization," Yposkesi's chief executive officer, Alain Lamproye, said in a press release. "The facility's state-of-the-art design will allow us, in collaboration with our clients, to manufacture advanced therapies more efficiently and cost-effectively in line with their C> pipelines and commitments, making these treatments more accessible to patients."
SK Inc. head of Bio Investment Center, Kim Yeon Tae Kim, also said they "anticipate Yposkesi to become a leading global Cell and Gene Therapy Contract Development and Manufacturing Organization through the synergy achieved with the Center for Breakthrough Medicines (CBM), a US-based cell and gene therapy CDMO and a subsidiary of SK pharmteco."
Photo by: SK Inc. Press Release
